Actively Recruiting
Assessment of Transcranial Alternating Current Stimulation's Clinical Efficacy in Treating Cognitive Impairment of Idiopathic Inflammatory Demyelinating Diseases
Led by Xuanwu Hospital, Beijing · Updated on 2025-07-28
128
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating idiopathic inflammatory demyelinating diseases (IIDDs) of the central nervous system, such as multiple sclerosis and neuromyelitis optica spectrum disease. The study aims to understand the brain imaging and electrical activity patterns in these conditions and how they relate to symptoms. It also explores the potential of transcranial electrical stimulation as a non-invasive therapy to relieve clinical symptoms and improve personalized treatment outcomes. Participants will be randomly assigned to one of two groups: one group will receive active transcranial electrical stimulation using the Spanish Neuroelectrics StarStim 32 device, while the other group will receive a placebo stimulation using the same equipment and procedures. This treatment period lasts 5 days, with evaluations conducted during and after the treatment phase to assess effects on disability and cognitive function. During the study, participants will undergo various assessments including the Expanded Disability Status Scale (EDSS), Symbol Digit Modalities Test (SDMT), and Alzheimer's disease assessment scale-cog (ADAS-cog) at the 5-day treatment point and one month after treatment ends. Additional cognitive and mood tests will also be performed. Researchers will monitor symptoms and any adverse effects daily during treatment. The total participation involves treatment and follow-up assessments to evaluate clinical improvements and safety.
CONDITIONS
Brief Title
Assessment of Transcranial Alternating Current Stimulation's Clinical Efficacy in Treating Cognitive Impairment of Idiopathic Inflammatory Demyelinating Diseases
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 60 years old
- Diagnosis of neuromyelitis optica spectrum disease, multiple sclerosis, or other inflammatory demyelinating diseases of the central nervous system
- Medications have been stable for at least three months
You will not qualify if you...
- Recurrence of disease recorded in the past 3 months
- Presence of a pacemaker or other metal implant in the body
- Impaired skin integrity at electrode placement sites
- History of organic brain diseases such as epilepsy, hydrocephalus, central nervous system tumors, brain injury, or intracranial infection
- Severe or unstable organ dysfunction such as heart, liver, or kidney problems
- Pregnant or breastfeeding women, or those planning pregnancy soon
- Poor compliance with study requirements
- Any condition deemed unsuitable for participation by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 5 days
Participants receive transcranial electrical stimulation or pseudo-stimulation using the Spanish Neuroelectrics StarStim 32 device.
Daily visits for 5 days
Duration - 1 month
Participants are monitored for clinical outcomes and adverse effects one month after the end of treatment.
1 visit (in-person)
Trial Site Locations
Total: 1 location
1
Xuanwu Hospital, Capital Medical University
Beijing, Beijing Municipality, China, 100053
Actively Recruiting
Research Team
H
huang huijin, Ph.D.
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here